Brief: Entrada Therapeutics Receives Authorization In United Kingdom To Initiate Phase 1 Clinical Trial Of ENTR-601-44 For Potential Treatment Of Duchenne Muscular Dystrophy
01/08/2023 12:03
Aug 1 (Reuters) - Entrada Therapeutics Inc TRDA.O :
* ENTRADA THERAPEUTICS RECEIVES AUTHORIZATION IN THE UNITED
KINGDOM TO INITIATE PHASE 1 CLINICAL TRIAL OF ENTR-601-44 FOR
THE POTENTIAL TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
* ENTRADA THERAPEUTICS INC - FIRST PARTICIPANT IS EXPECTED
TO BE
DOSED IN SEPTEMBER 2023 WITH DATA ANTICIPATED IN SECOND HALF OF
2024
* ENTRADA THERAPEUTICS INC - CASH RUNWAY EXTENDED THROUGH
END OF
2025
Source text for Eikon: ID:nGNX8JFXb5
Further company coverage: TRDA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entrada Therapeutics
See all newsBrief: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Entrada Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Entrada Therapeutics Q2 Collaboration Revenue USD 898 Thousand
Entrada Therapeutics Q2 net loss narrows on lower costs
Entrada Therapeutics Inc expected to post a loss of $1.05 a share - Earnings Preview